Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | The evolving treatment landscape of SCD

Robert Clark Brown • 24 Jun 2022
EHA 2022
Non-Malignant Sickle Cell Disease GBT021601 Hydroxyurea Voxelotor

Robert Clark Brown, MD, PhD, Aflac Cancer & Blood Disorders Center, Atlanta, GA, discusses advances in the field of sickle cell disease (SCD), discussing the mechanism of action of drugs such as voxelotor and GBT021601, and highlighting the promise of gene therapy and combination therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Consultancy: Global Blood Therapeutics, Imara, Novartis, Novo Nordisk; Research support: Global Blood Therapeutics, Forma Therapeutics, Imara, Novartis, Pfizer

More from Robert Clark Brown

GBT021601, a next generation HbS polymerization inhibitor for the treatment of SCD
2:16
GBT021601, a next generation HbS polymerization inhibitor for the treatment of SCD
Robert Clark Brown • 24 Jun 2022
Psychometric properties of a daily diary for patients with SCD
2:56
Psychometric properties of a daily diary for patients with SCD
Robert Clark Brown • 10 Jun 2021
The safety and efficacy of voxelotor in pediatric patients with SCD
1:15
The safety and efficacy of voxelotor in pediatric patients with SCD
Robert Clark Brown • 10 Jun 2021
Alternative clinical outcomes for patients receiving voxelotor for SCD
2:12
Alternative clinical outcomes for patients receiving voxelotor for SCD
Robert Clark Brown • 10 Jun 2021

Related Videos

Importance of long-term surveillance after gene therapy in patients with hemophilia
5:45
Importance of long-term surveillance after gene therapy in patients with hemophilia
Radek Kaczmarek • 20 Jul 2026
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
4:58
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
Radek Kaczmarek • 20 Jul 2026
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
5:18
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026
Understanding potential malignancy risk following AAV gene therapy in hemophilia
7:23
Understanding potential malignancy risk following AAV gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals